OSTX
OS Therapies Incorporated
NYSE MKT: OSTX · HEALTHCARE · BIOTECHNOLOGY
$1.70
+4.29% today
Updated 2026-04-30
Market cap
$77.20M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.98
Dividend yield
—
52W range
$1 – $3
Volume
0.6M
OS Therapies Incorporated (OSTX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — |
| Cost of revenue | $4250.00 | $1.16M | $805.00 | $4220.00 | $2780.00 | $363085.00 |
| Gross profit | $-4250.00 | $-1.16M | $-805.00 | $-4220.00 | $-2780.00 | $-363085.00 |
| Gross margin | — | — | — | — | — | — |
| R&D | $601.00 | $2.17M | $3.29M | $3.22M | $2.84M | $16.36B |
| SG&A | $795.00 | $1.50M | $1.15M | $1.12M | $3.97M | $12.34B |
| Operating income | $-5647.00 | $-4.84M | $-4.45M | $-4.34M | $-6.81M | $-28.71M |
| Operating margin | — | — | — | — | — | — |
| EBITDA | $-5647.00 | $-4.84M | $-4.45M | $-4.34M | $-6.83M | $-28.39M |
| EBITDA margin | — | — | — | — | — | — |
| EBIT | $-5647.00 | $-4.84M | $-4.45M | $-4.34M | $-6.83M | $-28.75M |
| Interest expense | $461.79M | $2.58M | $1.81M | $3.45M | $2.05M | $0.00 |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-6027.00 | $-7.42M | $-6.25M | $-7.79M | $-8.88M | $-28.75M |
| Net income growth (YoY) | — | -123016.8% | +15.7% | -24.6% | -14.0% | -223.7% |
| Profit margin | — | — | — | — | — | — |